Amneal Pharmaceuticals Receives FDA Approval for Cyclosporine Ophthalmic Emulsion 0.05%, Expanding Its Leadership in Complex Ophthalmic Therapies

Amneal receives FDA approval for cyclosporine ophthalmic emulsion 0.05%, a treatment for dry eye disease, launching in Q1 2026.

Quiver AI Summary

Amneal Pharmaceuticals has received FDA approval for its cyclosporine ophthalmic emulsion 0.05%, a preservative-free treatment for dry eye disease, which will be marketed as a generic version of RESTASIS. The product is supplied in single-use vials and is intended to enhance tear production in patients experiencing dryness due to ocular inflammation. With an annual market value of approximately $2 billion, this launch reinforces Amneal's expertise in complex sterile manufacturing and its growing focus on ophthalmic therapies. The company anticipates launching the product in the first quarter of 2026 as part of its wider strategy to expand its offerings in affordable medicines and maintain a strong presence in the healthcare sector.

Potential Positives

FDA approval of cyclosporine ophthalmic emulsion 0.05% enhances Amneal's portfolio in complex ophthalmic therapies, indicating strong capabilities in sterile manufacturing.
The product targets a significant market, with annual sales reaching approximately $2.0 billion, reflecting a substantial revenue opportunity for Amneal.
The launch of this product in Q1 2026 positions Amneal for growth and strengthens its leadership in the Affordable Medicines segment.

Potential Negatives

Approval of the new product may come too late to capture significant market share, as RESTASIS® has established itself and current market dynamics may hinder penetration.
The most common adverse reaction of ocular burning could limit patient acceptance and market success of the new product.
The reliance on complex manufacturing for this product may pose risks in terms of production capacity and quality control, potentially impacting future revenues.

FAQ

What recent FDA approval did Amneal Pharmaceuticals receive?

Amneal received FDA approval for cyclosporine ophthalmic emulsion 0.05%, a sterile, preservative-free formulation.

When is the launch date for the new cyclosporine formulation?

The launch of cyclosporine ophthalmic emulsion is expected in Q1 2026.

What is the primary use of cyclosporine ophthalmic emulsion?

The product is indicated to increase tear production in patients with dry eye syndrome due to ocular inflammation.

What are the common side effects of cyclosporine ophthalmic emulsion?

The most common adverse reaction is ocular burning.

How does Amneal plan to expand its product offerings?

Amneal aims to expand across complex product categories, including injectables and biosimilars within its Affordable Medicines segment.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$AMRX Insider Trading Activity

$AMRX insiders have traded $AMRX stock on the open market 14 times in the past 6 months. Of those trades, 0 have been purchases and 14 have been sales.

Here’s a breakdown of recent trading of $AMRX stock by insiders over the last 6 months:

TASOS KONIDARIS (Executive Vice President & CFO) has made 0 purchases and 3 sales selling 499,730 shares for an estimated $4,663,070.
NIKITA SHAH (Executive Vice President) has made 0 purchases and 5 sales selling 374,382 shares for an estimated $3,855,983.
ANDREW S BOYER (Executive Vice President) has made 0 purchases and 2 sales selling 312,680 shares for an estimated $2,921,904.
GAUTAM PATEL sold 94,906 shares for an estimated $761,146
TED C NARK sold 50,000 shares for an estimated $586,000
JOHN KIELY sold 32,000 shares for an estimated $295,360
JASON B. DALY (EVP, Chief Legal Officer) sold 22,000 shares for an estimated $199,100

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$AMRX had revenues of $784.5M in Q3 2025. This is an increase of 11.68% from the same period in the prior year.

You can track AMRX financials on Quiver Quantitative's AMRX stock page.

$AMRX Hedge Fund Activity

We have seen 138 institutional investors add shares of $AMRX stock to their portfolio, and 123 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

BLACKROCK, INC. added 1,942,294 shares (+16.0%) to their portfolio in Q3 2025, for an estimated $19,442,362
MILLENNIUM MANAGEMENT LLC removed 1,710,276 shares (-33.9%) from their portfolio in Q3 2025, for an estimated $17,119,862
WOODLINE PARTNERS LP removed 1,504,095 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $12,168,128
HENNESSY ADVISORS INC removed 1,499,400 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $12,130,146
ASSENAGON ASSET MANAGEMENT S.A. added 1,401,190 shares (+187.1%) to their portfolio in Q3 2025, for an estimated $14,025,911
WESTSHORE WEALTH, LLC added 1,381,910 shares (+inf%) to their portfolio in Q3 2025, for an estimated $13,832,919
BLACKBARN CAPITAL PARTNERS LP removed 1,257,118 shares (-36.5%) from their portfolio in Q3 2025, for an estimated $12,583,751

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$AMRX Analyst Ratings

Wall Street analysts have issued reports on $AMRX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Piper Sandler issued a "Overweight" rating on 10/31/2025

To track analyst ratings and price targets for $AMRX, check out Quiver Quantitative's $AMRX forecast page.

$AMRX Price Targets

Multiple analysts have issued price targets for $AMRX recently. We have seen 2 analysts offer price targets for $AMRX in the last 6 months, with a median target of $13.5.

Here are some recent targets:

David Amsellem from Piper Sandler set a target price of $13.0 on 10/31/2025
Chris Schott from JP Morgan set a target price of $14.0 on 09/16/2025

Full Release

Approval underscores Amneal’s advanced sterile manufacturing capabilities and expansion within complex ophthalmic therapies; Launch expected in Q1 2026

BRIDGEWATER, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved the Company’s cyclosporine ophthalmic emulsion 0.05%, a sterile, preservative-free formulation supplied in single-use vials. The product is the generic equivalent of RESTASIS ^® (cyclosporine ophthalmic emulsion) 0.05%, a registered trademark of Allergan, an AbbVie company.

“Dry eye disease affects millions of adults in the United States and can significantly impact their quality of life,” said Dr. Srinivas Kone, Senior Vice President, Chief Scientific Officer – Affordable Medicines. “We are proud to bring another difficult-to-manufacture ophthalmic product to market, reinforcing Amneal’s strong execution in complex formulations and our expanding leadership in ophthalmology within the Affordable Medicines segment. Cyclosporine joins a series of recent approvals across inhalation, injectable, and ophthalmic categories, underscoring Amneal’s strong execution in high-quality sterile manufacturing.”

Cyclosporine ophthalmic emulsion 0.05% is a topical immunomodulator indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with dry eye syndrome. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

The most common adverse reaction associated with cyclosporine ophthalmic emulsion 0.05% was ocular burning. Please see full Prescribing Information here .

According to IQVIA ^® U.S. annual sales for cyclosporine ophthalmic emulsion 0.05% in sterile, preservative-free single-use vials for the 12 months ended September 2025 were approximately $2.0 billion.

Note: RESTASIS ^® is a registered trademark of Allergan, an AbbVie company.

About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 290 pharmaceuticals, primarily within the United States. In its Affordable Medicines segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com and follow us on LinkedIn .

Cautionary Statement on Forward-Looking Statements
Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance; and statements regarding our positioning, including our ability to drive sustainable long-term growth, and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.

Investor Contact
Anthony DiMeo
VP, Investor Relations
[email protected]

Media Contact
Brandon Skop
Sr. Director, Corporate Communications
[email protected]